Cardiovascular effects and molecular mechanisms of bisphenol A and its metabolite MBP in zebrafish

A Ross Brown†, Jon M Green†, John Moreman†, Lina M Gunnarsson‡, Sulayman Mourabit†, Jonathan Ball†, Matthew J Winter†, Maciej Trznadel†, Ana Correia†, Christian Hacker†, Alexis Perry†, Mark E Wood†, Malcolm J Hetheridge†, Richard A Currie‡, Charles R Tyler†*

†Biosciences, College of Life and Environmental Sciences, University of Exeter, Geoffrey Pope, Stocker Road, Exeter, Devon, EX4 4QD, UK.
‡Jealott's Hill International Research Centre, Syngenta, Bracknell, Berkshire, RG42 6EY, UK.

* Corresponding author - Email: c.r.tyler@exeter.ac.uk.
Cardiovascular effects of BPA and MBP in zebrafish

Supporting Information

Contents

Table S1: The zebrafish heart and heart valve morphogenesis (valvulogenesis)……………………………………S3
Table S2: Water quality measured during BPA and MBP exposure studies……………………………………S4
Table S3: Test substances and analysis……………………………………………………………………………………………………S5
Table S4: BPA and MBP concentrations in water and zebrafish larvae………………………………………………S6
Table S5: Relative mean fluorescence intensity induced by BPA and MBP in the heart valves…S7
Table S6: Effects of BPA and MBP exposure on CV function in 15 dpf zebrafish larvae………………S8
Table S7: Effects of BPA and MBP exposure on specific growth rate (SGR) and critical swimming speed (U_{crit}) in 15 dpf zebrafish larvae………………………………………………………………………………………………………………………………………..S10
Table S8: Differentially expressed genes in BPA and MBP exposure treatments………………S12
Table S9: Enriched GO terms and KEGG pathways in BPA and MBP exposure treatments according to DAVID's Gene Functional Classification………………………………………………S13
Table S10: Enriched Reactome pathways in BPA and MBP exposure treatments………………S13
Table S11: Enriched Transcription Factor Binding Site motifs 5 kilobytes upstream of differentially expressed genes for BPA and MBP exposure treatments…………………………S13
Table S12: Enriched Transcription Factor Binding Site motifs 5 kilobytes downstream of differentially expressed genes for BPA and MBP exposure treatments…………………………S13
Table S13: Results summary for enriched transcription factor binding site motifs for EREs……S14

Figure S1: Nuclear Magnetic Resonance Spectrum for MBP……………………………………S15
Figure S2: Relative fluorescence in the hearts of ERE-GFP transgenic zebrafish larvae at 5 days and 15 days post fertilisation for exposure to BPA and MBP……………………………………S16
Figure S3: Effects of BPA and MBP exposure on specific growth rate (SGR) and critical swimming speed (U_{crit}) in zebrafish larvae at 15 days post fertilisation (dpf)……………………………S17
Figure S4: Differential gene expression in heart tissue sampled from BPA and MBP exposure treatments versus solvent controls in larval zebrafish at 5 days post fertilisation (dpf)………S18
Figure S5: Differential gene expression in heart tissue sampled from BPA and MBP exposure treatments versus solvent controls in larval zebrafish at 15 days post fertilisation (dpf)……S19
Figure S6: Venn diagrams showing overlap in differentially expressed genes in zebrafish (versus respective solvent controls) for BPA and for MBP exposure treatments………………S20
Figure S7: Venn diagrams showing overlap in differentially expressed genes in zebrafish (versus respective solvent controls) at 5 and 15 dpf…………………………………………………S20
Figure S8: Gene set enrichment for Reactome pathways in heart tissues from 5 and 15 day old larval zebrafish in BPA and MBP exposure treatments (versus solvent controls)………………S21
Figure S9: Enriched Transcription Factor Binding Site motifs 5 kb up- and down- stream of differentially expressed genes for BPA and MBP exposure treatments……………………………S22

References…………………………………………………………………………………………………………………………………..S23
Cardiovascular effects of BPA and MBP in zebrafish

Table S1: The zebrafish heart and heart valve morphogenesis (valvulogenesis)

The zebrafish heart comprises a single atrium and ventricle, as opposed to two atria and a single ventricle in reptiles and amphibians, or two atria and two ventricles in birds and mammals (Stainier, 2001). Single circuit, systemic blood circulation in the zebrafish is regulated by three valves separating the sinus venosus-atrium, atrium-ventricle, ventricle-bulbus arteriosus, each of which help to minimise retrograde blood flow (Hu et al., 2000; Tessadori et al., 2012). In air breathing vertebrates there is a systemic circuit and a pulmonary (lung) circuit. Despite these gross morphological differences, the cellular and molecular architectures of the zebrafish heart, including the heart valves, are highly similar to those in mammals (Beis et al., 2005) and clearly illustrate the common evolutionary origin of these structures (Staudt and Stainier, 2012).

The bulbo-ventricular canal (BVC) and the atrio-ventricular canal (AVC), which are precursors to the BV and AV valves respectively, can be distinguished at 36 hours post fertilisation (hpf) (Mehta et al., 2008) and the sinus venosus valve is distinguishable by 48 hpf (Grimes et al., 2006). Initial valvulogenesis (formation of the endocardial rings) is completed shortly after 96 hpf (Hu et al., 2000; Grimes et al., 2006) and is described in detail for the atrio-ventricular valve (Hove et al., 2003; Bartman et al., 2004; Vermot et al., 2009; Staudt and Stainier, 2012; Chen et al., 2013), but not the bulbo-ventricular valve or sinus venosus valve. By 48 hpf, the AVC endocardium thickens to form the endocardial ring, and by 55 hpf this consists of a single layer of polarized cuboidal endocardial cells that stain strongly for alcama (Scherz et al., 2008). Cuboidal cell formation and alcama expression is dependent on troponin T type 2a (tnnt2a) (Bartman et al., 2004; Beis et al., 2005). The cuboidal endocardial cell layer subsequently proliferates, folds and extends into the extracellular matrix to form the superior valve leaflet by 85 hpf, and the inferior leaflet by 102 hpf (Scherz et al., 2008). The valve leaflets consist of two layers of cells, with those in the layer closest to the AVC remaining cuboidal and those in the layer closest to the myocardium developing a rounded shape (Scherz et al., 2008). Heart valve formation and remodelling (e.g. AV valve transitioning from two to four leaflets) is completed by 35 dpf (Beis et al., 2005; Sarmah et al., 2016). At the a molecular level, initial formation of the AVC coincides with localised expression of bmp4, versican (cspg2) and tgfβ in the AVC myocardium (Walsh and Stainier, 2001; Beis et al., 2005; Chen et al., 2013) and expression of notch1b, calcineurin (ppp3ca, b, c and ppp3r1, 2) (Beis et al., 2005); has2 (Hurelstone et al., 2003) and prss23 (Chen et al., 2013) in the AVC endocardium. Key genes (e.g. notch1b and bmp4) in gene networks regulating endocardial cell proliferation and valve morphogenesis (post 48 hpf) have been linked to Wnt/β-catenin signalling (Walsh and Stainier, 2001; Hurlestone et al., 2003), TGF-β, ErbB/Neuregulin and prostaglandin signalling (Scherz et al., 2008) and to pkd2/Hdac5/Klf signalling (Vermot et al., 2009).
Cardiovascular effects of BPA and MBP in zebrafish

Table S2: Water quality measured during BPA and MBP exposure studies

| Exposure treatment | Temperature (°C) | pH  | Dissolved oxygen (%) | Ammonia (µg/L NH₃) | Hardness (mg/L CaCO₃) |
|--------------------|-----------------|-----|----------------------|--------------------|-----------------------|
| BPA (0-5 dpf)      | 27.4-28.1       | 7.7-7.8 | 84-98             | 1.7-2.2           | 100-125               |
| BPA (0-15 dpf)     | 26.8-27.9       | 7.7-7.9 | 79-96              | 1.4-3.2           | 100-125               |
| MBP (0-5 dpf)      | 27.7-28.0       | 7.5-7.9 | 74-91              | 1.6-2.3           | 100-125               |
| MBP (0-15 dpf)     | 26.7-27.9       | 7.4-7.8 | 87-93              | 1.5-2.9           | 100-125               |

Data represent the range in water quality measurements for solvent controls, low and high-level exposure treatments in each study.
Cardiovascular effects of BPA and MBP in zebrafish

Table S3: Test substances and analysis

| Chemical Abstracts Service (CAS) Number | Compound name | Structure |
|----------------------------------------|---------------|-----------|
| 80-05-7                                | BPA 2,2-Bis(4-hydroxyphenyl)propane | ![BPA Structure](image) |
| 13464-24-9                             | MBP 4-methyl-2,4-bis(4-hydroxyphenyl)pent-l-ene | ![MBP Structure](image) |

Analytical method

Analysis of water and tissue samples was performed by Liquid Chromatography and Mass Spectrometry (LC-MS).

Chromatographic separation was achieved using a reversed-phase, 3 μm particle size, C18 Hypersil GOLD column (50 mm × 2.1 mm i.d., Thermo Scientific, San Jose CA, USA).

Both analytes were separated using a linear gradient of (A) aqueous phase and (B) organic solvent with initial conditions shown in the table below. Solvent B increased to 100% in 4.5 min and this was maintained for 1 min, before returning to the initial condition. The flow rate was 500µL/min. Temperature of autosampler was set at 8°C, while column was kept at a room temperature.

| Analyte | (A) Aqueous phase | (B) Organic phase | Initial conditions (% of B) |
|---------|-------------------|-------------------|----------------------------|
| BPA     | Water             | Methanol          | 10                         |
| MBP     | Water             | Methanol          | 10                         |

Mass spectrometry was performed using a TSQ Vantage triple quadrupole mass spectrometer. The mass spectrometer was equipped with a heated electrospray (HESI II) source (ThermoFisher Scientific, Hemel Hempstead, UK). The HESI probe was operating in both negative and positive mode; an ion-spray voltage of -4.0 kV for both analytes. The heated capillary temperature was set at 275 °C and the vaporizer temperature was 60 °C. Nitrogen was employed as a sheath and auxiliary gas at a pressure of 60 and 2 arbitrary units, respectively.

The argon CID gas was used at a pressure of 1.5 mTorr and the optimum collision energy (CE) for each transition was selected. Quantification of the target compounds was performed by monitoring two characteristic multiple reaction monitoring (MRM) transitions (Table below).

| Analyte | Parent ion (m/z) | Product ion (m/z) | CE (eV) |
|---------|------------------|-------------------|---------|
| BPA     | 227              | 133.1             | 23      |
|         |                   | 117.0             | 49      |
| MBP     | 267.1            | 212.1             | 20      |
|         |                   | 133.1             | 28      |
Cardiovascular effects of BPA and MBP in zebrafish

Table S4: BPA and MBP concentrations in water and zebrafish larvae (5 days post fertilization)

| Aqueous exposure conc. (µg/L) | Replicate aquaria | Measured aqueous conc. (µg/L) | Measured whole body conc. # (ng/g) | Bio-concentration factor ¥ | Measured heart conc. § (ng/g) | Bio-concentration factor ¥ |
|-------------------------------|-------------------|-------------------------------|-----------------------------------|---------------------------|-------------------------------|---------------------------|
| BPA exposure study            |                   |                               |                                   |                           |                               |                           |
| Solvent Control               | 1                 | 0                             | < LOD                             | 0                         | 0                             | 0                         |
|                               | 2                 | 0                             | < LOD                             | 0                         | 0                             | 0                         |
|                               | 3                 | 0                             | < LOD                             | 0                         | 0                             | 0                         |
| 100                           | 1                 | 115                           | 270                               | 2.6                       | -                             | -                         |
|                               | 2                 | 108                           | 257                               | 2.5                       | -                             | -                         |
|                               | 3                 | 128                           | 240                               | 2.4                       | -                             | -                         |
| 1000                          | 1                 | 1069                          | 3190                              | 3.2                       | 62                            | 0.06                      |
|                               | 2                 | 1051                          | 3660                              | 3.7                       | 57                            | 0.06                      |
|                               | 3                 | 1042                          | 4390                              | 4.5                       | 140                           | 0.14                      |
| MBP exposure study            |                   |                               |                                   |                           |                               |                           |
| Solvent Control               | 1                 | 0                             | < LOD                             | 0                         | -                             | -                         |
|                               | 2                 | 0                             | < LOD                             | 0                         | -                             | -                         |
|                               | 3                 | 0                             | < LOD                             | 0                         | -                             | -                         |
| 2.5                           | 1                 | 2.4                           | -                                 | -                         | -                             | -                         |
|                               | 2                 | 2.0                           | -                                 | -                         | -                             | -                         |
|                               | 3                 | 1.8                           | -                                 | -                         | -                             | -                         |
| 25                            | 1                 | 28                            | 705                               | 25.2                      | -                             | -                         |
|                               | 2                 | 29                            | 732                               | 25.3                      | -                             | -                         |
|                               | 3                 | 27                            | 592                               | 21.9                      | -                             | -                         |

Data are presented as the mean ± 95% confidence interval.

# Whole body concentration was calculated based on a wet weight of 1200 µg for a single zebrafish larvae at 5 days post fertilization (dpf) (Hu et al., 2000).

§ Heart concentration was calculated based on a ventricle weight of 10% of the whole body weight at 5 dpf (Hu et al., 2000).

¥ Bio-concentration factor (BCF) was calculated as measured tissue concentration / measured aqueous exposure concentration.

Aqueous exposure concentrations were relatively stable of over time. During the longest period between the static renewal of exposure solutions (i.e. 0-5 days), maximum reductions in aqueous exposure concentrations were: 34% for BPA (from 108% to 74% of nominal for the 100 µg/L exposure); 29% for MBP (from 96% to 67% of nominal for the 2.5 µg/L exposure).
Cardiovascular effects of BPA and MBP in zebrafish

**Table S5: Relative mean fluorescence intensity induced by BPA and MBP in the heart valves**

|                        | 5 dpf       | 15 dpf       |
|------------------------|-------------|--------------|
| **BPA exposure (µg/L)**| 100         | 1000         |
| Heart valve fluorescence| 2.2 ± 0.3   | 31 ± 2       |
|                        | 100         | 1000         |
|                        | 15.3 ± 1.1  | 26.9 ± 0.2   |
| **MBP exposure (µg/L)**| 2.5         | 25           |
| Heart valve fluorescence| 34 ± 3     | 54 ± 5       |
|                        | 2.5         | 25           |
|                        | 3.0 ± 0.4   | 14.6 ± 1.5   |

Relative mean fluorescence intensity of the ERE:GFP reporter was quantified relative to the solvent control at 5 and 15 days post fertilization (dpf). Data are presented as the mean ± 95% confidence interval.
Cardiovascular effects of BPA and MBP in zebrafish

Table S6: Effects of BPA and MBP exposure on cardiovascular function in 15 dpf zebrafish larvae

Results

| Exposure Treatment | Heart beat rate (bpm) | Blood flow (nL/s) |
|--------------------|-----------------------|-------------------|
| BPA Exposure       |                       |                   |
| 0                  | 241 ± 4               | 2.01 ± 0.06       |
| 100                | 251 ± 2               | 2.16 ± 0.08       |
| 1000               | 250 ± 4               | 2.15 ± 0.08       |
| MBP Exposure       |                       |                   |
| 0                  | 249 ± 7               | 1.95 ± 0.06       |
| 2.5                | 243 ± 4               | 1.69 ± 0.08       |
| 25                 | 218 ± 4               | 1.55 ± 0.07       |

Data are presented as the mean ± 95% confidence interval.

MANOVA analysis with tank as a random effect

LME model fit with aquarium as a random effect

MBP Treatment 1 = control, Treatment 2 = Low (2.5 µg/L), Treatment 3 = High (25 µg/L)

Response = 'Blood flow' AND 'Heart beat rate'

model = lme(cbind(Blood.flow, Heart.beat.rate) ~ Treatment, random=~1|Aquarium, data = dat)

| AIC      | BIC      | logLik   |
|----------|----------|----------|
| 71.15566 | 77.63485 | -30.57783 |

Df Pillai approx F num Df den Df Pr(>F)
Treatment 2 0.36586 3.0225 4 54 0.02539 *
Residuals 27

Response = 'Blood flow'

model = lme(Blood.flow ~ Treatment, random=~1|Tank1, data=dat)

| AIC      | BIC      | logLik   |
|----------|----------|----------|
| 71.15566 | 77.63485 | -30.57783 |

Random effects: (Intercept). Residual StdDev: 0.2323506 0.6288888

Fixed effects: Blood.flow ~ Treatment

| Value    | Std.Error | DF  | t-value | p-value |
|----------|-----------|-----|---------|---------|
| (Intercept) | 3.916218  | 0.2349573 | 17 | 16.667790 | 0.0000 |
| Treatment2 | -0.540965 | 0.3239045 | 10 | -1.670138 | 0.1258 |
Cardiovascular effects of BPA and MBP in zebrafish

Treatment3 -0.831637 0.3296337 10 -2.522912 **0.0302**
Correlation: (Intr) Trtmn2; Treatment2 -0.725; Treatment3 -0.713 0.517

Standardized Within-Group Residuals:

|        | Min         | Q1         | Med         | Q3         | Max         |
|--------|-------------|------------|-------------|------------|-------------|
| Standardized Within-Group Residuals | -1.8354989 | -0.6211684 | -0.1157832 | 0.6755835  | 1.9765751   |

Number of Observations: 30
Number of Groups: 13

**Response = 'Heart beat'**

model = lme(Heart.beat.rate ~ Treatment, random=-1|Tank1, data=dat)

|        | AIC      | BIC      | logLik   |
|--------|----------|----------|----------|
| Random effects: (Intercept). Residual StdDev:  | 263.076 269.5552 -126.538 | 8.827086 21.79687 |

Fixed effects: Heart.beat.rate ~ Treatment

| Value  | Std.Error | DF  | t-value | p-value |
|--------|-----------|-----|---------|---------|
| (Intercept) 249.72992  | 8.308052  | 17  | 30.058780 | 0.000   |
| Treatment2 -7.10923  | 11.491302 | 10  | -0.618661 | 0.550   |
| Treatment3 -31.34922 | 11.686427 | 10  | -2.682532 | **0.023** |

Correlation: (Intr) Trtmn2; Treatment2 -0.723; Treatment3 -0.711 0.514

Standardized Within-Group Residuals:

|        | Min         | Q1         | Med         | Q3         | Max         |
|--------|-------------|------------|-------------|------------|-------------|
| Standardized Within-Group Residuals | -2.4816596 | -0.5578130 | 0.1658430  | 0.6262645  | 1.3984753   |

Number of Observations: 30
Number of Groups: 13
Cardiovascular effects of BPA and MBP in zebrafish

Table S7: Effects of BPA and MBP exposure on specific growth rate (SGR) and critical swimming speed ($U_{\text{critb}}$) in 15 dpf zebrafish larvae

Results

| Exposure Treatment | SGR (% standard body length per day) | $U_{\text{critb}}$ (body lengths/sec) |
|--------------------|-------------------------------------|--------------------------------------|
| BPA Exposure       |                                     |                                      |
| 0                  | 1.37 ± 0.10                         | 12.72 ± 0.23                         |
| 100                | 1.32 ± 0.07                         | 12.28 ± 0.20                         |
| 1000               | 1.44 ± 0.06                         | 11.82 ± 0.19                         |
| MBP Exposure       |                                     |                                      |
| 0                  | 1.36 ± 0.15                         | 12.61 ± 0.44                         |
| 2.5                | 0.96 ± 0.11                         | 11.70 ± 0.43                         |
| 25                 | 1.06 ± 0.07                         | 10.73 ± 0.40                         |

Data are presented as the mean ± 95% confidence interval.

LME model fit with aquarium as a random effect

MBP Treatment 1 = control, Treatment 2 = Low (2.5 µg/L), Treatment 3 = High (25 µg/L)

Response = ‘$U_{\text{critb}}$’

model = lme($U_{\text{critb}}$ ~ Treatment, random=~1|Aquarium, data=dat)

AIC  BIC  logLik
255.7234 265.1825 -122.8617

Random effects: Tank (Intercept) Residual StdDev: 0.4352544 2.694444

Fixed effects: $U_{\text{critb}}$ ~ Treatment

| Value       | Std.Error | DF  | t-value | p-value |
|-------------|-----------|-----|---------|---------|
| (Intercept) | 10.992396 | 0.5900421 | 36 | 18.62985 | 0.0000 |
| Treatment2  | -0.819231 | 0.9344436 | 13 | -0.876705 | 0.3966 |
| Treatment3  | -1.667611 | 0.9514960 | 13 | -1.752620 | 0.1032 |

Correlation: (Intr) Trtmn2: Treatment2 -0.631; Treatment3 -0.620 0.392

Standardized Within-Group Residuals:

| Min    | Q1    | Med   | Q3    | Max    |
|--------|-------|-------|-------|--------|
| -2.3945383 | -0.5321397 | -0.1088102 | 0.5557497 | 2.3296676 |

Number of Observations: 52
Number of Groups: 16
Response = ‘Specific Growth Rate’
model = lme(SGR ~ Treatment, random=~1|Aquarium, data=log.dat)

Linear mixed-effects model fit by REML
   AIC   BIC  logLik
26.83093 30.37118 -8.415466

Random effects: Aquarium (Intercept) Residual
StdDev: 0.3319166 0.1244687

Fixed effects: SGR ~ Treatment
                      Value   Std.Error   DF  t-value    p-value
(Intercept)         1.1797476 0.1447187  15  8.152003 0.0000
Treatment2          -0.3403799 0.2046632  15 -1.663122 0.1170
Treatment3          -0.2560214 0.2046632  15 -1.250940 0.2301

Correlation: (Intr) Trtmn2: Treatment2 -0.707; Treatment3 -0.707 0.500

Standardized Within-Group Residuals:
                     Min            Q1           Med            Q3           Max
-0.5324397885 -0.2427571025  0.0007605993  0.2696808931  0.6679405905

Number of Observations: 18
Number of Groups: 18
Cardiovascular effects of BPA and MBP in zebrafish

Table S8: Differentially expressed genes in BPA and MBP exposure treatments

**In the low-level BPA exposure** (100 µg/L) 131 genes were differentially expressed at 5 dpf and only 1 gene apolipoprotein Da, duplicate 2 (apoda.2 - associated with GO:0006810 ~transport) at 15 dpf (SI Table S8 .xls). At 5 dpf there was significant enrichment of genes / ontologies associated with transport: GO:0006810 ~transport, GO:0006811 ~ion transport, GO:0055085 ~transmembrane transport, GO:0035879 ~plasma membrane lactate transport. Cell signalling pathways were also enriched GO:0007219 ~Notch signalling pathway, dre04630:Jak-STAT signalling pathway, dre04060:Cytokine-cytokine receptor interaction, dre04080:Neuroactive ligand-receptor interaction (SI Table S9a.xls).

In the high-level BPA (1000 µg/L) 371 genes were differentially expressed at 5 dpf: 62 of these genes were consistent with the low-level BPA exposure treatment at 5 dpf; 5 genes were consistent with the high-level BPA exposure treatment at 15 dpf - for which there was a total of 32 differentially expressed genes (SI Table S8 .xls). There were three distinct gene groups at 5 dpf with significantly enriched ontologies for i) ‘Cellular and extracellular matrix interactions’ including via KEGG pathways dre04510:Focal adhesion, dre04512:ECM-receptor interaction, and the following processes GO:0005509 ~calcium ion binding, GO:0003171 ~atrioventricular valve development, GO:0060347 ~heart trabecula formation; ii) ‘Transcriptional regulation’ including via dre04330:Notch signalling, GO:0001947 ~heart looping, GO:0003146 ~heart jogging, GO:0002040 ~sprouting angiogenesis; iii) ‘Protein metabolism’ including GO:0006508 ~proteolysis, GO:0008544 ~epidermis development, GO:0030199 ~collagen fibril organization, GO:0060429 ~epithelium development (SI Table S9c.xls).

At 15 dpf the most notable among the 32 differentially expressed (down-regulated) genes were: actinin alpha 3b (actn3b), myosin light chain, phosphorylatable, fast skeletal muscle a (mylpfa), myosin, heavy polypeptide 2, fast muscle specific (myh2) associated with KEGG pathways: dre04510~ Focal adhesion, dre04520 ~Adherens junction, dre04530 ~Tight junction, dre04810 ~Regulation of actin cytoskeleton. Other differentially expressed genes at 15 dpf included insulin-like growth factor 1a receptor (igf1ra) associated with GO:0007507 ~heart development, and troponin I type 2a (skeletal, fast), tandem duplicate 4 (tnni2a.4) associated with GO:0030239 ~myofibril assembly, GO:0060048 ~cardiac muscle contraction (SI Table S9c.xls).

**Low-level MBP exposure** (2.5 µg/L) resulted in differential expression (down-regulation) of 8 genes at 5 dpf, associated with cellular respiration: dre00010:Glycolysis/Gluconeogenesis, oxidative stress and immune response: dre00480:Glutathione metabolism, GO:000590:Arachidonic acid metabolism, and also cell signalling: dre04310:Wnt signalling pathway. Only one (unannotated) gene (si:dkey-7c18.24) was differentially expressed at 15 dpf (SI Table 8 .xls).

**High-level MBP exposure** (25 µg/L) resulted in differential expression (predominantly down-regulation) of 127 genes at 5 dpf. One of these genes: elastin microfibril interfacser 3 (emilin3) was consistent with the low-level MBP exposure treatment at 5 dpf, and 2 genes: activated leukocyte cell adhesion molecule b (alcamb) and transforming growth factor, beta-induced (tgfbi) were consistent with that seen for the high-level BPA exposure treatment (SI Table S8 .xls). There were two distinct gene groups with significantly enriched ontologies for i) ‘Cellular and extracellular matrix interactions’ including via KEGG pathways dre04510:Focal adhesion, dre04512:ECM-receptor interaction, and the process GO:0060536 ~cartilage morphogenesis; ii) ‘Filamentous protein synthesis and activity’ including GO:0045095 ~keratin filament, GO:0005882 ~intermediate filament, GO:0005198 ~structural molecule activity (Table 9d.xls). The transcriptomic effects of high-level MBP exposure at 15 dpf could not be established due to problems encountered in sample processing (PCR amplification of libraries).
Cardiovascular effects of BPA and MBP in zebrafish

See separate file: ‘Supplemental Information Tables S8 to S12.xls’ for the following tables.

Table S8: Differentially expressed genes in BPA and MBP exposure treatments (continued)

Table S9: Enriched GO terms and KEGG pathways in BPA and MBP exposure treatments according to DAVID’s Gene Functional Classification

Table S10: Enriched Reactome pathways in BPA and MBP exposure treatments

Table S11: Enriched Transcription Factor Binding Site motifs 5 kilobytes upstream of differentially expressed genes for BPA and MBP exposure treatments

Table S12: Enriched Transcription Factor Binding Site motifs 5 kilobytes downstream of differentially expressed genes for BPA and MBP exposure treatments
Cardiovascular effects of BPA and MBP in zebrafish

Table S13: Results summary for enriched transcription factor binding site motifs for EREs

| Test chemical | Exposure conc (μg/L) | Time point (dpf) | up/down-stream | Proximal flanking regions (5 kB) | Distal flanking regions (50 kB) |
|---------------|---------------------|------------------|----------------|---------------------------------|---------------------------------|
|               |                     |                  |                | sp1    | sp3    | sp4    | creb1  | creb5  | nfb2   | foxa1  | runx1  | esr2   | esr1   | esr2   |
| BPA           | 100                 | 5                | up             | ✓      | ✓      | ✓      | ✓                  | ✓                      | ✓                      | ✓                      | ✓                      | ✓                      | ✓                      |
|               |                     |                  | down           | ✓      | ✓      | ✓      | ✓                  | ✓                      | ✓                      | ✓                      | ✓                      | ✓                      | ✓                      |
|               | 1000                | 5                | up             | ✓      | ✓      | ✓      | ✓      | ✓      | ✓      | ✓        | ✓        | ✓        | ✓        |
|               |                     |                  | down           | ✓      | ✓      | ✓      | ✓      | ✓      | ✓      | ✓        | ✓        | ✓        | ✓        |
|               | 1000                | 15               | up             | ✓      | ✓      | ✓      | ✓      | ✓      | ✓      | ✓        | ✓        | ✓        | ✓        |
| MBP           | 2.5                 | 5                | up             | ✓      | ✓      | ✓      | ✓      | ✓      | ✓      | ✓        | ✓        | ✓        | ✓        |
|               |                     |                  | down           | ✓      | ✓      | ✓      | ✓      | ✓      | ✓      | ✓        | ✓        | ✓        | ✓        |
|               | 25                  | 5                | up             | ✓      | ✓      | ✓      | ✓      | ✓      | ✓      | ✓        | ✓        | ✓        | ✓        |
|               |                     |                  | down           | ✓      | ✓      | ✓      | ✓      | ✓      | ✓      | ✓        | ✓        | ✓        | ✓        |

Proximal flanking regions 5 kB up- and down-stream of differentially expressed genes are generally considered to be rich in ERE binding sites and other transcription factor binding sites related to estrogen receptor (ER)-signalling including: estrogen receptors (esr1, esr2); specificity proteins constituting ERE tethering factors (sp1, sp3, sp4); pioneer factors facilitating ER binding (foxa1, nfb2, pbx1, runx1); CAMP responsive element binding proteins (creb1, creb5).

Distal enhancer or promoter elements (up to 100 kB) are also involved in regulating the expression of many estrogen receptor target genes, often through looping or other higher order chromatin structures (reviewed in Dietz and Carroll, 2008; Liu and Cheung, 2014; Magnani and Lupien, 2014). This highlights the difficulties in pinning down the regulation of individual genes by estrogen receptors and the benefit of wider scanning of flanking regions for sets of genes to evaluate enrichment of TFBS motifs for ER-related transcription factor binding. We elected to scan 50 kB up- and down-stream of our differentially expressed genes, since the mean intergenic region in zebrafish is 97 kB, with a standard deviation of 164 kB (Hu et al., 2015). Therefore scanning ±100 kB would have a high risk of overlapping genes.

S14
4-Methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene (MBP) was synthesised at the University of Exeter. The final purity of MBP was 99%.
Cardiovascular effects of BPA and MBP in zebrafish

Figure S2: Relative fluorescence in the hearts of ERE-GFP transgenic zebrafish larvae at 5 days and 15 days post fertilization for exposure to BPA and MBP

Relative mean fluorescence intensity was quantified relative to the solvent controls to account for any background auto-fluorescence. Mean fluorescence was quantified from 6 individual fish taken randomly from each of 6 separate aquaria (n=6 experimental replicates) per exposure treatment. Error bars represent 95% confidence intervals.
Cardiovascular effects of BPA and MBP in zebrafish

Figure S3: Effects of BPA and MBP exposure on specific growth rate (SGR) and critical swimming speed ($U_{critb}$) in zebrafish larvae at 15 days post fertilisation (dpf)

Hatched bar charts (A-B) represent BPA, solid bar charts (C-D) represent MBP. Bar heights represent means, error bars represent 95% confidence intervals. There were no significant effects at ($p<0.05$).
Cardiovascular effects of BPA and MBP in zebrafish

Figure S4. Differential gene expression in heart tissue sampled from BPA and MBP exposure treatments versus solvent controls in larval zebrafish at 5 days post fertilization (dpf)

Differential gene expression in embryo-larval heart tissues was assessed using DESeq2 (Love et al., 2014). An adjusted p-value of <0.05 was set as the false discovery rate. The most differentially expressed genes (top 50, maximum) are shown: colour gradient light-dark represents low-high gene expression. Data for experiment treatment replicates were generated from hearts pooled from ~30 individual from each of 4 separate aquaria (nominally n=4 experimental replicates) per exposure treatment.
Cardiovascular effects of BPA and MBP in zebrafish

Day 15 100 μg/l BPA v Control

Only one gene was expressed differentially between treatments (apolipoprotein Da, duplicate 2 (apoda.2))

Day 15 1000 μg/l BPA v Control

Differential gene expression in heart tissue sampled from chemical exposure treatments versus solvent controls at 15 days post fertilisation (dpf)

Differential gene expression in embryo-larval heart tissues was assessed using DESeq2 (Love et al., 2014). An adjusted p-value of <0.05 was set as the false discovery rate. The most differentially expressed genes (top 50, maximum) are shown: colour gradient light-dark represents low-high gene expression. Data for experiment treatment replicates were generated from hearts pooled from ~30 individual from each of 4 separate aquaria (nominally n=4 experimental replicates) per exposure treatment.

Figure S5: Differential gene expression in heart tissue sampled from chemical exposure treatments versus solvent controls at 15 days post fertilisation (dpf)
Cardiovascular effects of BPA and MBP in zebrafish

Figure S6: Venn diagrams showing overlap in differentially expressed genes in zebrafish (versus respective solvent controls) for BPA and for MBP exposure treatments.

Figure S7: Venn diagrams showing overlap in differentially expressed genes in zebrafish (versus respective solvent controls) for both BPA and MBP at 5 and 15 days post fertilisation (dpf).
Cardiovascular effects of BPA and MBP in zebrafish

Figure S8: Gene set enrichment for Reactome pathways in heart tissues from 5 and 15 day old larval zebrafish in BPA and MBP exposure treatments (versus solvent controls).

Sequence data were generated from hearts pooled from ~30 individuals from each of 4 separate aquaria (nominally n=4 experimental replicates) per exposure treatment. Enriched pathways were identified using Enrichr and referenced to the Reactome database (2016). Pathways highlighted in red boxes are calcific aortic valve disease (CAVD) biomarkers.
Enriched transcription factor binding site motifs were identified using Analysis of Motif Enrichment (AME) in MEME suite 5.0.2. Enrichment is inversely proportional to adjusted $p$-value. Transcription factor binding site motifs associated with estrogen receptor signalling, included: estrogen receptor 2 (esr2); specificity proteins constituting ERE tethering factors ($sp1$, $sp3$, $sp4$); pioneer factors facilitating ERE binding ($foxa1$, $nfbk2$, $pbx1$, $runx1$); CAMP responsive element binding proteins ($creb1$, $creb5$).
Cardiovascular effects of BPA and MBP in zebrafish

References

Bartman T, Walsh EC, Wen KK, McKane M, Ren J, Alexander J, Rubenstein PA, Stainier DY. Early myocardial function affects endocardial cushion development in zebrafish. *PLoS Biol.* 2004, 2(5), E129. PMID: 15138499, DOI: 10.1371/journal.pbio.0020129.

Beis D, Bartman T, Jin SW, Scott IC, D’Amico LA, Ober EA et al. Genetic and cellular analyses of zebrafish atrioventricular cushion and valve development. *Development* 2005, 132, 4193–4204. PMID: 16107477, DOI: 10.1242/dev.01970.

Chen IH, Wang HH, Hsieh YS, Huang WC, Yeh HI, Chuang YJ. PRSS23 is essential for the Snail-dependent endothelial-to-mesenchymal transition during valvulogenesis in zebrafish. *Cardiovasc. Res.* 2013, 97(3), 443–453. PMID: 23213106, DOI: 10.1093/cvr/cvs355.

Dietz SC, Carroll JS. Interrogating the genome to understand oestrogen-receptor-mediated transcription. *Expert. Rev. Mol. Med.* 2008, 10:e10. PMID: 18377699 DOI: 10.1017/S1462399408000653.

Grimes AC, Stadt HA, Shepherd IT, Kirby ML. Solving an enigma: arterial pole development in the zebrafish heart. *Dev. Biol.* 2006, 290(2), 265–276. PMID: 16405941, DOI: 10.1016/j.ydbio.2005.11.042.

Hu N, Sedmera D, Yost HJ, Clark EB. Structure and function of the developing zebrafish heart. *Anat. Rec.* 2000, 260(2), 148–57. PMID: 10993952, DOI: 10.1002/1097-0185(20001001)260:2<148::AID-AR50>3.0.CO;2-X.

Hu P, Liu M, Zhang D, Wang J, Niu H, Liu Y, Wu Z, Han B, Zhai W, Shen Y, Chen L. Global identification of the genetic networks and cis-regulatory elements of the cold response in zebrafish. *Nucleic Acids Res.* 2015, 43(19), 9198–9213. PMID: 26227973, DOI: 10.1093/nar/gkv780.

Hurlstone AFL, Haramis A-PG, Wienholds E, Begthel H, Korving J, van Eeden F, Cuppen E, Zivkovic D, Plasterk RHA, Clevers H. The Wnt/β-catenin pathway regulates cardiac valve formation. *Nature* 2003, 425(6958), 633–637. PMID: 14534590, DOI: 10.1038/nature02028.

Liu MH, Cheung E. Estrogen receptor-mediated long-range chromatin interactions and transcription in breast cancer. *Mol. Cell. Endocrinol.* 2014, 382(1), 624–632. PMID: 24071518 DOI: 10.1016/j.mce.2013.09.019.

Magnani L, Lupien M. Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signalling. *Mol. Cell. Endocrinol.* 2014, 382(1), 633–641. PMID: 23684889 DOI: 10.1016/j.mce.2013.04.026

Mehta V, Peterson, RE, Heideman, W. 2,3,7,8-Tetrachlorodibenzo-p-dioxin exposure prevents cardiac valve formation in developing zebrafish. *Toxicol. Sci.* 2008, 104(2), 303–311. PMID: 18477685, DOI: 10.1093/toxsci/kfn095.

Sarmah S, Marrs JA. Zebrafish as a vertebrate model system to evaluate effects of environmental toxicants on cardiac development and function. *Int. J. Mol. Sci.* 2016, 17(12), 2123. PMID: 27999267, DOI: 10.3390/ijms17122123.
Cardiovascular effects of BPA and MBP in zebrafish

Scherz PJ, Huiskens J, Sahai-Hernandez P, Stainier DYR. High-speed imaging of developing heart valves reveals interplay of morphogenesis and function. *Development* 2008, 135(6):1179–1187. PMID: 18272595, DOI: 10.1242/dev.010694.

Stainier DY. Zebrafish genetics and vertebrate heart formation. *Nat. Rev. Genet.* 2001, 2, 39–48. PMID: 11253067, DOI: 10.1038/35047564.

Staudt D, Stainier D. Uncovering the molecular and cellular mechanisms of heart development using the zebrafish. *Annu. Rev. Genet.* 2012, 46, 397–418. PMID: 22974299, DOI: 10.1146/annurev-genet-110711-155646.

Tessadori F, van Weerd JH, Burkhard SB, Verkerk AO, de Pater E, Boukens BJ, Vink A, Christoffels VM, Bakkers J. Identification and functional characterization of cardiac pacemaker cells in zebrafish. *PLoS One* 2012, 7(10):e47644. PMID: 23077655, DOI: 10.1371/journal.pone.0047644.

Vermot J, Forouhar AS, Liebling M, Wu D, Plummer D, Gharib M, Fraser SE. Reversing blood flows act through *klf2a* to ensure normal valvulogenesis in the developing heart. *PLoS Biol.* 2009, 7(11):e1000246. PMID: 19924233, DOI: 10.1371/journal.pbio.1000246.

Walsh EC, Stainier DY. UDP-glucose dehydrogenase required for cardiac valve formation in zebrafish. *Science* 2001, 293(5535), 1670–1673. PMID: 11533493, DOI: 10.1126/science.293.5535.1670